{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:06:44Z","timestamp":1787026004957,"version":"build-2736575974"},"reference-count":213,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR135829"],"award-info":[{"award-number":["NIHR135829"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Cystic fibrosis is a life-limiting genetic condition that affects over 9000 people in England. Cystic fibrosis is usually diagnosed through newborn screening and causes symptoms throughout the body, including the lungs and digestive system. Around 90% of individuals with cystic fibrosis have at least one copy of the\n                      <jats:italic>F508del<\/jats:italic>\n                      mutation on the cystic fibrosis transmembrane conductance regulator gene.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To appraise the clinical effectiveness and cost-effectiveness of elexacaftor\u2013tezacaftor\u2013ivacaftor, tezacaftor\u2013ivacaftor and lumacaftor\u2013ivacaftor within their expected marketing authorisations for treating people with cystic fibrosis and at least one\n                      <jats:italic>F508del<\/jats:italic>\n                      mutation, compared with each other and with established clinical management before these treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A de novo systematic literature review (search date February 2023) was conducted searching electronic databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials), bibliographies of relevant systematic literature reviews, clinical trial registers, recent conferences and evidence provided by Vertex Pharmaceuticals (Boston, MA, USA). Data on the following outcomes were summarised: acute change in per cent predicted forced expiratory volume in 1 second (change in weight-for-age\n                      <jats:italic>z<\/jats:italic>\n                      -score; and change in pulmonary exacerbation frequency requiring intravenous antibiotics. Network meta-analyses were conducted where head-to-head data were not available. Data from clinical trials and real-world evidence were examined to assess long-term effectiveness. A patient-level simulation model was developed to assess the cost-effectiveness of the three modulator treatments. The model employed a lifetime horizon and was developed from the perspective of the National\u00a0Health\u00a0Service.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Data from 19 primary studies and 7 open-label extension studies were prioritised in the systematic literature review. Elexacaftor\/tezacaftor\/ivacaftor was associated with a statistically significant increase in predicted forced expiratory volume in 1 second and weight-for-age\n                      <jats:italic>z<\/jats:italic>\n                      -score and a reduction in pulmonary exacerbations compared with established clinical management, lumacaftor\/ivacaftor and tezacaftor\/ivacaftor, and also led to a reduction in the rate of predicted forced expiratory volume in 1 second decline relative to established clinical management, although the magnitude of this decrease was uncertain. Lumacaftor\/ivacaftor and tezacaftor\/ivacaftor were also associated with a statistically significant increase in predicted forced expiratory volume in 1 second and reduction in pulmonary exacerbations relative to established clinical management, but with a smaller effect size than elexacaftor\/tezacaftor\/ivacaftor. There was some evidence that tezacaftor\/ivacaftor reduced the rate of predicted forced expiratory volume in 1 second decline relative to established clinical management, but little evidence that lumacaftor\/ivacaftor reduced the rate of predicted forced expiratory volume in 1 second decline relative to established clinical management. The incremental cost-effectiveness ratios from the economic analysis were confidential. However, for all genotypes studied the incremental cost-effectiveness ratios were above what would be considered cost-effective based on the National Institute for Health and Care Excellence threshold of \u00a320,000\u201330,000 per quality-adjusted life-year gained.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite the improved clinical benefits observed, none of the cystic fibrosis transmembrane conductance regulator gene modulators assessed would be considered cost-effective based on the National Institute for Health and Care Excellence threshold of \u00a320,000\u201330,000 per quality-adjusted life-year gained. This is largely driven by the high acquisition costs of cystic fibrosis transmembrane conductance regulator gene modulator treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-6\">\n                    <jats:title>Study registration<\/jats:title>\n                    <jats:p>This study is registered as PROSPERO CRD42023399583.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-7\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>\n                      This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR135829) and is published in full in\n                      <jats:italic>Health Technology Assessment<\/jats:italic>\n                      ; Vol. 29, No. 19. See the NIHR Funding and Awards website for further award information.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/cpld8546","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T02:49:27Z","timestamp":1728874167000},"page":"1-111","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Ivacaftor\u2013tezacaftor\u2013elexacaftor, tezacaftor\u2013ivacaftor and lumacaftor\u2013ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9049-3421","authenticated-orcid":true,"given":"Steven J","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-6133","authenticated-orcid":true,"given":"Benjamin G","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4284-217X","authenticated-orcid":true,"given":"Kate","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0496-9671","authenticated-orcid":true,"given":"Nicole","family":"Downes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2058-6411","authenticated-orcid":true,"given":"Victoria","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1604-7326","authenticated-orcid":true,"given":"Isaac","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6614-8452","authenticated-orcid":true,"given":"Archie","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8041-0346","authenticated-orcid":true,"given":"Tracey","family":"Jhita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,5]]},"reference":[{"key":"key2025052621071600_ref1-bib1","unstructured":"Cystic Fibrosis Trust. UK Cystic Fibrosis Registry: 2021 Annual Data Report. London: Cystic Fibrosis Trust; 2022."},{"key":"key2025052621071600_ref2-bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/thoraxjnl-2019-213179","article-title":"Impact of newborn screening on outcomes and social inequalities in cystic fibrosis: a UK CF registry-based study","volume":"75","author":"Schluter","year":"2020","journal-title":"Thorax"},{"key":"key2025052621071600_ref3-bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s41030-022-00202-y","article-title":"Rate of lung function decline in people with cystic fibrosis having a residual function gene mutation","volume":"8","author":"Sawicki","year":"2022","journal-title":"Pulmonary Ther"},{"key":"key2025052621071600_ref4-bib4","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"key2025052621071600_ref5-bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0092-8674(95)90240-6","article-title":"Degradation of CFTR by the ubiquitin\u2013proteasome pathway","volume":"83","author":"Ward","year":"1995","journal-title":"Cell"},{"key":"key2025052621071600_ref6-bib6","doi-asserted-by":"crossref","first-page":"106878","DOI":"10.1016\/j.rmed.2022.106878","article-title":"Who are the 10%? \u2013 non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies","volume":"199","author":"Desai","year":"2022","journal-title":"Respir Med"},{"key":"key2025052621071600_ref8-bib8","volume-title":"Cystic Fibrosis: Diagnosis and Management (NG78)","author":"National Institute for Health and Care Excellence","year":"2017"},{"key":"key2025052621071600_ref9-bib9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/resp.13174","article-title":"Rescue therapy within the UK Cystic Fibrosis Registry: an exploration of predictors of intravenous antibiotic use amongst adults with CF","volume":"23","author":"Hoo","year":"2018","journal-title":"Respirology"},{"key":"key2025052621071600_ref10-bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jcf.2020.04.008","article-title":"Average rate of lung function decline in adults with cystic fibrosis in the United Kingdom: data from the UK CF registry","volume":"20","author":"Caley","year":"2021","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref11-bib11","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref12-bib12","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/JOE-18-0468","article-title":"Survival in a bad neighborhood: pancreatic islets in cystic fibrosis","volume":"241","author":"Norris","year":"2019","journal-title":"J Endocrinol"},{"key":"key2025052621071600_ref13-bib13","doi-asserted-by":"crossref","first-page":"a009746","DOI":"10.1101\/cshperspect.a009746","article-title":"The cystic fibrosis of exocrine pancreas","volume":"3","author":"Wilschanski","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"key2025052621071600_ref14-bib14","doi-asserted-by":"crossref","first-page":"e000614","DOI":"10.1136\/bmjresp-2020-000614","article-title":"How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey","volume":"7","author":"Smith","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"key2025052621071600_ref15-bib15","unstructured":"Cystic Fibrosis Trust. UK Cystic Fibrosis Registry: 2019 Annual Data Report. London: Cystic Fibrosis Trust; 2020."},{"key":"key2025052621071600_ref16-bib16","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1513\/AnnalsATS.202209-829OC","article-title":"Lung function decline in cystic fibrosis: impact of data availability and modeling strategies on clinical interpretations","volume":"20","author":"Szczesniak","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"key2025052621071600_ref17-bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ije\/dyx196","article-title":"Data Resource Profile: the UK Cystic Fibrosis Registry","volume":"47","author":"Taylor-Robinson","year":"2018","journal-title":"Int J Epidemiol"},{"key":"key2025052621071600_ref18-bib18","volume-title":"Data Collection Agreement. 2020","author":"National Institute for Health and Care Excellence (NICE)","year":"2020"},{"key":"key2025052621071600_ref19-bib19","volume-title":"Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines","author":"Vertex Pharmaceuticals Inc","year":"2019"},{"key":"key2025052621071600_ref20-bib20","volume-title":"Cystic Fibrosis Complications and Symptoms","author":"Cystic Fibrosis Trust","year":"n.d."},{"key":"key2025052621071600_ref21-bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.med.0000436191.87727.ec","article-title":"Cystic fibrosis-related bone disease: insights into a growing problem","volume":"20","author":"Stalvey","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"key2025052621071600_ref22-bib22","first-page":"136","article-title":"Liver disease in cystic fibrosis","volume":"9","author":"Kobelska-Dubiel","year":"2014","journal-title":"Prz Gastroenterol"},{"key":"key2025052621071600_ref23-bib23","volume-title":"Fertility and Cystic Fibrosis","author":"Cystic Fibrosis Trust","year":"n.d."},{"key":"key2025052621071600_ref24-bib24","unstructured":"Cystic Fibrosis Trust. Cystic Fibrosis Insight Survey \u2013 Report on the 2017 and 2018 Surveys. London: Cystic Fibrosis Trust; 2019."},{"key":"key2025052621071600_ref31-bib31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12913-015-1061-3","article-title":"Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom","volume":"15","author":"Angelis","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"key2025052621071600_ref32-bib32","doi-asserted-by":"crossref","first-page":"17534666221086416","DOI":"10.1177\/17534666221086416","article-title":"Caregiver burden in cystic fibrosis: a systematic literature review","volume":"16","author":"Daly","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"key2025052621071600_ref33-bib33","doi-asserted-by":"crossref","first-page":"e12381","DOI":"10.2196\/12381","article-title":"Quality of life among informal caregivers of patients with degenerative cervical myelopathy: cross-sectional questionnaire study","volume":"8","author":"Mowforth","year":"2019","journal-title":"Interact J Med Res"},{"key":"key2025052621071600_ref36-bib36","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1513\/AnnalsATS.201408-393OC","article-title":"A systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis","volume":"12","author":"Habib","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"key2025052621071600_ref37-bib37","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/healthcare10071351","article-title":"Health-related quality of life in adults with cystic fibrosis: familial, occupational, social, and mental health predictors","volume":"10","author":"Ancel","year":"2022","journal-title":"Healthcare"},{"key":"key2025052621071600_ref38-bib38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"key":"key2025052621071600_ref39-bib39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"key2025052621071600_ref40-bib40","doi-asserted-by":"crossref","first-page":"18)","DOI":"10.3310\/hta18180","article-title":"Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis","volume":"18","author":"Whiting","year":"2014","journal-title":"Health Technol Assess"},{"key":"key2025052621071600_ref41-bib41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12955-016-0465-z","article-title":"Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis","volume":"14","author":"Solem","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"key2025052621071600_ref42-bib42","volume-title":"UK Population Norms for EQ-5D. Discussion Paper 172","author":"Kind","year":"1999"},{"key":"key2025052621071600_ref43-bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1022037320039","article-title":"Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients","volume":"12","author":"Henry","year":"2003","journal-title":"Qual Life Res"},{"key":"key2025052621071600_ref44-bib44","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","article-title":"Development and validation of the Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis","volume":"128","author":"Quittner","year":"2005","journal-title":"Chest"},{"key":"key2025052621071600_ref45-bib45","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jcf.2018.12.004","article-title":"Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis","volume":"18","author":"Flume","year":"2019","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref46-bib46","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jcf.2020.02.017","article-title":"Changes in the parent Cystic Fibrosis Questionnaire-Revised (CFQ-R) with respiratory symptoms in preschool children with cystic fibrosis","volume":"19","author":"Perrem","year":"2020","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref47-bib47","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40271-019-00361-2","article-title":"Validity and reliability of a novel multimodal questionnaire for the assessment of abdominal symptoms in people with cystic fibrosis (CFAbd-Score)","volume":"12","author":"Jaudszus","year":"2019","journal-title":"Patient"},{"key":"key2025052621071600_ref48-bib48","volume-title":"The Financial Costs of Cystic Fibrosis","author":"Evans","year":"2023"},{"key":"key2025052621071600_ref49-bib49","first-page":"725","article-title":"Changes in the normal maximal expiratory flow-volume curve with growth and aging","volume":"127","author":"Knudson","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"key2025052621071600_ref50-bib50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1164\/ajrccm.159.1.9712108","article-title":"Spirometric reference values from a sample of the general U.S. population","volume":"159","author":"Hankinson","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"key2025052621071600_ref51-bib51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ppul.1950150204","article-title":"Pulmonary function between 6 and 18 years of age","volume":"15","author":"Wang","year":"1993","journal-title":"Pediatr Pulmonol"},{"key":"key2025052621071600_ref52-bib52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1164\/rccm.200708-1248OC","article-title":"Reference ranges for spirometry across all ages: a new approach","volume":"177","author":"Stanojevic","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"key2025052621071600_ref53-bib53","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the Global Lung Function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"key2025052621071600_ref54-bib54","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1002\/ppul.25059","article-title":"Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor\/ivacaftor treatment","volume":"55","author":"Ejiofor","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"key2025052621071600_ref55-bib55","doi-asserted-by":"crossref","first-page":"00094","DOI":"10.1183\/23120541.00094-2017","article-title":"The clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trials","volume":"4","author":"Foong","year":"2018","journal-title":"ERJ Open Res"},{"key":"key2025052621071600_ref56-bib56","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1164\/rccm.200911-1646OC","article-title":"Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis","volume":"183","author":"Aurora","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"key2025052621071600_ref57-bib57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.00159111","article-title":"Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis","volume":"40","author":"Waters","year":"2012","journal-title":"Eur Respir J"},{"key":"key2025052621071600_ref58-bib58","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ppul.21374","article-title":"Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis","volume":"46","author":"Sanders","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"key2025052621071600_ref59-bib59","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"key2025052621071600_ref60-bib60","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"key2025052621071600_ref61-bib61","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/thoraxjnl-2020-216265","article-title":"Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials","volume":"77","author":"Keogh","year":"2022","journal-title":"Thorax"},{"key":"key2025052621071600_ref62-bib62","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3389\/fmicb.2017.01592","article-title":"Burkholderia cenocepacia infections in cystic fibrosis patients: drug resistance and therapeutic approaches","volume":"8","author":"Scoffone","year":"2017","journal-title":"Front Microbiol"},{"key":"key2025052621071600_ref63-bib63","volume-title":"TA266 Mannitol Dry Powder for Inhalation for Treating Cystic Fibrosis","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"key2025052621071600_ref64-bib64","volume-title":"TA276 Colistimethate Sodium and Tobramycin Dry Powders for Inhalation for Treating Pseudomonas Lung Infection in Cystic Fibrosis","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key2025052621071600_ref65-bib65","volume-title":"Kalydeco 25\u2009mg Granules in Sachet","author":"Electronic Medicines Compendium","year":"2022"},{"key":"key2025052621071600_ref66-bib66","volume-title":"Kalydeco 150\u2009mg Film-Coated Tablets","author":"Electronic Medicines Compendium","year":"2022"},{"key":"key2025052621071600_ref67-bib67","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","article-title":"VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1","volume":"24","author":"Ren","year":"2013","journal-title":"Mol Biol Cell"},{"key":"key2025052621071600_ref68-bib68","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores DeltaF508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat Chem Biol"},{"key":"key2025052621071600_ref69-bib69","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor\u2013tezacaftor\u2013ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"key2025052621071600_ref70-bib70","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref71-bib71","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"key2025052621071600_ref72-bib72","volume-title":"Orkambi 100\u2009mg\/125\u2009mg Film Coated Tablets","author":"Electronic Medicines Compendium","year":"2021"},{"key":"key2025052621071600_ref73-bib73","volume-title":"Orkambi 100\u2009mg\/125\u2009mg Granules in Sachet","author":"Electronic Medicines Compendium","year":"2021"},{"key":"key2025052621071600_ref74-bib74","volume-title":"Lumacaftor\u2013Ivacaftor for Treating Cystic Fibrosis Homozygous for the F508del Mutation","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"key2025052621071600_ref75-bib75","volume-title":"Symkevi 100\u2009mg\/150\u2009mg tablets PLGB 22352\/0003","author":"Electronic Medicines Compendium","year":"2021"},{"key":"key2025052621071600_ref76-bib76","volume-title":"Kaftrio 75\u2009mg 50\u2009mg 100\u2009mg Film-Coated Tablets","author":"Electronic Medicines Compendium","year":"2021"},{"key":"key2025052621071600_ref77-bib77","volume-title":"Kaftrio 60\u2009mg\/40\u2009mg\/80\u2009mg Granules in Sachet","author":"Electronic Medicines Compendium","year":"2023"},{"key":"key2025052621071600_ref78-bib78","volume-title":"Ivacaftor\u2013Tezacaftor\u2013Elexacaftor, Tezacaftor\u2013Ivacaftor and Lumacaftor\u2013Ivacaftor for Treating Cystic Fibrosis [ID3834]: Final Scope","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2025052621071600_ref80-bib80","unstructured":"Cystic Fibrosis Trust. UK Cystic Fibrosis Registry: 2022 Annual Data Report. London: Cystic Fibrosis Trust; 2023."},{"key":"key2025052621071600_ref81-bib81","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"key2025052621071600_ref82-bib82","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/thoraxjnl-2011-200953","article-title":"Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study","volume":"67","author":"Taylor-Robinson","year":"2012","journal-title":"Thorax"},{"key":"key2025052621071600_ref84-bib84","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcf.2022.07.010","article-title":"Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening","volume":"22","author":"McColley","year":"2023","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref85-bib85","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcf.2017.01.016","article-title":"Ethnicity impacts the cystic fibrosis diagnosis: a note of caution","volume":"16","author":"Bosch","year":"2017","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref86-bib86","volume-title":"Public Committee Slides 20 June 2024","author":"National Institute for Health and Care Excellence","year":"2024"},{"key":"key2025052621071600_ref88-bib88","volume-title":"Ivacaftor\u2013Tezacaftor\u2013Elexacaftor, Tezacaftor\u2013Ivacaftor and Lumacaftor\u2013Ivacaftor for Treating Cystic Fibrosis [ID3834]. Committee Papers 3 November 2023","author":"National Institute for Health and Care Excellence (NICE)","year":"2023"},{"key":"key2025052621071600_ref89-bib89","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key2025052621071600_ref90-bib90","volume-title":"Final Protocol. Elexacaftor\u2013Tezacaftor\u2013Ivacaftor, Lumacaftor\u2013Ivacaftor and Tezacaftor\u2013Ivacaftor for Treating Cystic Fibrosis [ID3834]","author":"BMJ Technology Assessment Group","year":"2023"},{"key":"key2025052621071600_ref91-bib91","first-page":"CD010966","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","volume":"12","author":"Southern","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"key2025052621071600_ref93-bib93","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2025052621071600_ref94-bib94","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"key2025052621071600_ref95-bib95","volume-title":"25.5 Risk of Bias in Uncontrolled Before\u2013After Studies (Including Interrupted Time Series)","author":"Sterne","year":"2023"},{"key":"key2025052621071600_ref96-bib96","first-page":"3546","article-title":"CADTH reimbursement review elexacaftor\u2013tezacaftor\u2013ivacaftor and ivacaftor (Trikafta)","volume":"2","author":"Canadian Agency for Drugs and Technologies in Health","year":"2022","journal-title":"Can J Health Technol"},{"key":"key2025052621071600_ref97-bib97","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials: Report by the Decision Support Unit","author":"Dias","year":"2016"},{"key":"key2025052621071600_ref98-bib98","volume-title":"gemtc: Network Meta-Analysis Using Bayesian Methods: R Package Version 1.0-1","author":"van Valkenhoef","year":"2021"},{"key":"key2025052621071600_ref99-bib99","volume-title":"18 Stansummary: MCMC Output Analysis","author":"Stan Development Team","year":"n.d."},{"key":"key2025052621071600_ref100-bib100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/14740338.2015.994503","article-title":"Efficacy and adverse effects of drugs used to treat adult cystic fibrosis","volume":"14","author":"Chopra","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"key2025052621071600_ref101-bib101","first-page":"121","article-title":"CFTR modulator guidelines","volume":"52","author":"Naureckas","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"key2025052621071600_ref102-bib102","first-page":"A6269","article-title":"Clinical efficacy and safety of CFTR-directed therapies in cystic fibrosis: a systematic review and meta-analysis","volume":"197","author":"Habib","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"key2025052621071600_ref103-bib103","first-page":"CD010966","article-title":"Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis","volume":"2018","author":"Southern","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"key2025052621071600_ref104-bib104","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1513\/AnnalsATS.201707-539OT","article-title":"Cystic fibrosis foundation pulmonary guidelines: use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis","volume":"15","author":"Ren","year":"2018","journal-title":"Ann Am Thoracic Soc"},{"key":"key2025052621071600_ref105-bib105","doi-asserted-by":"crossref","first-page":"S842","DOI":"10.1016\/j.jval.2019.09.2340","article-title":"Pro8 efficacy of CFTR modulators against pulmonary exacerbation in cystic fibrosis: a systematic review and network meta-analysis","volume":"22","author":"Takyar","year":"2019","journal-title":"Value Health"},{"key":"key2025052621071600_ref106-bib106","first-page":"529","article-title":"Non-respiratory effects of CFTR modulators in pediatric patients with cystic fibrosis: a systematic review","volume":"26","author":"Tronzon","year":"2021","journal-title":"J Pediatric Pharmacol Therapeutics"},{"key":"key2025052621071600_ref107-bib107","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"Bailey","year":"2021","journal-title":"J Acad Nutr Dietet"},{"key":"key2025052621071600_ref108-bib108","first-page":"33","article-title":"A systematic Cochrane review of corrector therapies (with or without potentiators) for people with cystic fibrosis with class II gene variants (most commonly F508DEL) [1]","volume":"38","author":"Southern","year":"2021","journal-title":"Paediatr Respir Rev"},{"key":"key2025052621071600_ref109-bib109","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1016\/j.jval.2021.11.840","article-title":"POSA273 systematic review, meta-analysis of per OS administered drugs in cystic fibrosis","volume":"25","author":"Koutsovasili","year":"2022","journal-title":"Value Health"},{"key":"key2025052621071600_ref110-bib110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/2772432818666230201094115","article-title":"Cystic fibrosis transmembrane conductance regulator protein modulators in children and adolescents with different CF genotypes \u2013 systematic review and meta-analysis","volume":"19","author":"Yousif Hamdan","year":"2023","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"key2025052621071600_ref111-bib111","first-page":"e29359","article-title":"Newly discovered cutting-edge triple combination cystic fibrosis therapy: a systematic review","volume":"14","author":"Dawood","year":"2022","journal-title":"Cureus"},{"key":"key2025052621071600_ref112-bib112","first-page":"CD009841","article-title":"Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis","volume":"2015","author":"Patel","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key2025052621071600_ref113-bib113","first-page":"25","article-title":"A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis [1]","volume":"30","author":"Southern","year":"2019","journal-title":"Paediatr Respir Rev"},{"key":"key2025052621071600_ref114-bib114","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key2025052621071600_ref115-bib115","doi-asserted-by":"crossref","first-page":"e024537","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"key":"key2025052621071600_ref116-bib116","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"key":"key2025052621071600_ref117-bib117","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-Gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"key2025052621071600_ref118-bib118","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"key2025052621071600_ref119-bib119","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"key2025052621071600_ref120-bib120","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of ELX\/TEZ\/IVA in children 6 through 11 years of age with CF and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Critical Care Med"},{"key":"key2025052621071600_ref121-bib121","volume-title":"Evaluation of ELX\/TEZ\/IVA in Cystic Fibrosis (CF) Subjects 2 through 5 Years","author":"ClinicalTrials.gov","year":"2020"},{"key":"key2025052621071600_ref122-bib122","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"key2025052621071600_ref123-bib123","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"key2025052621071600_ref124-bib124","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","article-title":"A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation","volume":"20","author":"Davies","year":"2021","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref125-bib125","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2020.12.006","article-title":"VO2max as an exercise tolerance endpoint in people with cystic fibrosis: lessons from a lumacaftor\/ivacaftor trial","volume":"20","author":"Wilson","year":"2021","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref126-bib126","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6\u201311 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"key2025052621071600_ref127-bib127","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(21)00981-4","article-title":"An exploratory study to determine the impact of lumacaftor\/ivacaftor (LUM\/IVA) on disease progression in children 2 through 5 years of age with cystic fibrosis homozygous for F508del-CFTR (F\/F)","volume":"20","author":"Stahl","year":"2021","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref128-bib128","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"key2025052621071600_ref129-bib129","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"key2025052621071600_ref130-bib130","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref131-bib131","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor treatment: randomized trial in subjects with cystic fibrosis who have an R117H-CFTR mutation","volume":"3","author":"Moss","year":"2015","journal-title":"Lancet Respir Med"},{"key":"key2025052621071600_ref132-bib132","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S1569-1993(22)00861-X","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study","volume":"21","author":"Griese","year":"2022","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref133-bib133","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/S1569-1993(21)01985-8","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in children aged 6 and older with cystic fibrosis and at least 1 F508del allele: interim results from a Phase 3 open-label extension study","volume":"20","author":"Ratjen","year":"2021","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref134-bib134","volume-title":"NCT04058366: Study Evaluating the Long-Term Safety and Efficacy of VX-445 Combination Therapy","author":"ClinicalTrials.gov","year":"2023"},{"key":"key2025052621071600_ref135-bib135","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"},{"key":"key2025052621071600_ref136-bib136","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcf.2022.02.003","article-title":"A phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor\/ivacaftor in children >= 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant","volume":"21","author":"Sawicki","year":"2022","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref137-bib137","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jcf.2019.06.009","article-title":"A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis","volume":"18","author":"Walker","year":"2019","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref138-bib138","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"key2025052621071600_ref139-bib139","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2213-2600(20)30517-8","article-title":"Long-term safety and efficacy of lumacaftor\u2013ivacaftor therapy in children aged 6\u201311 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study","volume":"9","author":"Chilvers","year":"2021","journal-title":"Lancet Respir Med"},{"key":"key2025052621071600_ref140-bib140","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.201608-1754OC","article-title":"Lumacaftor\/Ivacaftor in patients aged 6\u201311 years with cystic fibrosis and homozygous for F508del-CFTR","volume":"195","author":"Milla","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"key2025052621071600_ref141-bib141","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcf.2022.09.006","article-title":"Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic","volume":"22","author":"Doumit","year":"2023","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref142-bib142","doi-asserted-by":"crossref","first-page":"e0255659","DOI":"10.1371\/journal.pone.0255659","article-title":"Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis","volume":"16","author":"Alqahtani","year":"2021","journal-title":"PLOS ONE"},{"key":"key2025052621071600_ref143-bib143","unstructured":"Vertex Pharmaceuticals Inc. Clinical Study Report. Protocol VX20-445-111. A Phase 3 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Elexacaftor\/Tezacaftor\/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 through 5 Years of Age. Unpublished. Boston, MA; 2022."},{"key":"key2025052621071600_ref144-bib144","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jcf.2017.09.012","article-title":"Lumacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR","volume":"17","author":"Taylor-Cousar","year":"2018","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref145-bib145","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2021.08.014","article-title":"Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?","volume":"21","author":"Granger","year":"2022","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref146-bib146","volume-title":"Lumacaftor\u2013Ivacaftor for Treating Cystic Fibrosis Homozygous for the F508del Mutation [TA398]","author":"NICE","year":"2016"},{"key":"key2025052621071600_ref147-bib147","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jpeds.2012.10.008","article-title":"Evolution of pancreatic function during the first year in infants with cystic fibrosis","volume":"162","author":"O\u2019Sullivan","year":"2013","journal-title":"J Pediatr"},{"key":"key2025052621071600_ref148-bib148","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/path.4634","article-title":"Pancreatic pathophysiology in cystic fibrosis","volume":"238","author":"Gibson-Corley","year":"2016","journal-title":"J Pathol"},{"key":"key2025052621071600_ref149-bib149","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jcf.2021.12.006","article-title":"Rescue of chloride and bicarbonate transport by elexacaftor\u2013ivacaftor\u2013tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers","volume":"21","author":"Bijvelds","year":"2022","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref151-bib151","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jcf.2017.10.003","article-title":"Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation","volume":"17","author":"Wagener","year":"2018","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref152-bib152","unstructured":"UK Cystic Fibrosis Registry. 2021 Annual Data Report. 2022."},{"key":"key2025052621071600_ref153-bib153","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLOS Med"},{"key":"key2025052621071600_ref154-bib154","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/EDE.0000000000000920","article-title":"Dynamic prediction of survival in cystic fibrosis: a landmarking analysis using UK Patient Registry data","volume":"30","author":"Keogh","year":"2019","journal-title":"Epidemiology"},{"key":"key2025052621071600_ref155-bib155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"key":"key2025052621071600_ref156-bib156","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/ppul.25250","article-title":"Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic","volume":"56","author":"Patel","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"key2025052621071600_ref157-bib157","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/medicina58010066","article-title":"Impact of COVID-19 on hospital admissions for COPD exacerbation: lessons for future care","volume":"58","author":"Lawless","year":"2022","journal-title":"Medicina"},{"key":"key2025052621071600_ref158-bib158","unstructured":"Vertex Pharmaceuticals Inc. AURORA F\/RF F\/G OLE (Study 110): Clinical Study Report \u2013 Part A: A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of VX-445 Combination Therapy in Subjects with Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F\/G and F\/RF Genotypes). Version 1.0, Protocol Number: VX18-445-110. Unpublished. Boston, MA; 2022."},{"key":"key2025052621071600_ref159-bib159","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/aje\/kwab263","article-title":"Using negative control outcomes and difference-in-differences analysis to estimate treatment effects in an entirely treated cohort: the effect of ivacaftor in cystic fibrosis","volume":"191","author":"Newsome","year":"2022","journal-title":"Am J Epidemiol"},{"key":"key2025052621071600_ref160-bib160","article-title":"TP084. Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor (ELX\/TEZ\/IVA) in people with cystic fibrosis (CF) and at least one F508del allele: an open-label, 192-week extension study","volume":"29","author":"Selvadurai","year":"2024","journal-title":"Respirology"},{"key":"key2025052621071600_ref162-bib162","unstructured":"Vertex Pharmaceuticals Inc. Clinical Study Report. A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of VX-445 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation. Unpublished. Boston, MA; 2023."},{"key":"key2025052621071600_ref163-bib163","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref164-bib164","volume-title":"NCT04058366. Study Evaluating the Long-Term Safety and Efficacy of VX-445 Combination Therapy","author":"ClinicalTrials.gov","year":"2024"},{"key":"key2025052621071600_ref165-bib165","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/jcm10071527","article-title":"Real-world outcomes of ivacaftor treatment in people with cystic fibrosis: a systematic review","volume":"10","author":"Duckers","year":"2021","journal-title":"J Clin Med"},{"key":"key2025052621071600_ref166-bib166","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1569-1993(18)30287-X","article-title":"CF-EpiNet. IPD2.03: the effects of 3-year ivacaftor use on lung function and intravenous days seen in UK CF Registry data","volume":"17","author":"Newsome","year":"2018","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref167-bib167","unstructured":"UK CF Registry. Data Request Report \u2013 469. London: Cystic Fibrosis Trust; 2023."},{"key":"key2025052621071600_ref168-bib168","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"key2025052621071600_ref169-bib169","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jcf.2018.08.004","article-title":"Investigating the effects of long-term dornase alfa use on lung function using registry data","volume":"18","author":"Newsome","year":"2019","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref170-bib170","volume-title":"ISRCTN14081521: A Randomised Open-Label Trial to Assess Change in Respiratory Function for People with Cystic Fibrosis (pwCF) Established on Triple Combination Therapy (Kaftrio\u2122) after Rationalisation of Nebulised Mucoactive Therapies (the CF STORM Trial)","author":"Southern","year":"2021"},{"key":"key2025052621071600_ref171-bib171","volume-title":"NCT05519020: Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis","author":"ClinicalTrials.gov","year":"2022"},{"key":"key2025052621071600_ref172-bib172","unstructured":"Vertex Pharmaceuticals Inc. Clinical Study Report. Protocol VX16-809-122. A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor\/Ivacaftor in Subjects 1 to Less Than 2 Years of Age with Cystic Fibrosis, Homozygous for F508del. Unpublished. Boston, MA; 2022."},{"key":"key2025052621071600_ref173-bib173","volume-title":"Economic Evaluations and Models \u2013 MEDLINE","author":"Canadian Agency for Drugs and Technologies in Health","year":"2016"},{"key":"key2025052621071600_ref174-bib174","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1017\/S0266462317000897","article-title":"Performance of Ovid MEDLINE search filters to identify health state utility studies","volume":"33","author":"Arber","year":"2017","journal-title":"Int J Technol Assess Health Care"},{"key":"key2025052621071600_ref175-bib175","doi-asserted-by":"crossref","first-page":"276","DOI":"10.18553\/jmcp.2021.27.2.276","article-title":"The effectiveness and value of novel treatments for cystic fibrosis","volume":"27","author":"Tice","year":"2021","journal-title":"J Managed Care Specialty Pharm"},{"key":"key2025052621071600_ref176-bib176","first-page":"285","article-title":"Cost-effectiveness and budget impact of lumacaftor","volume":"25","author":"Vadagam","year":"2019","journal-title":"J Managed Care Specialty Pharm"},{"key":"key2025052621071600_ref179-bib179","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jval.2017.06.014","article-title":"Forecasting the long-term clinical and economic outcomes of lumacaftor\/ivacaftor in cystic fibrosis patients with homozygous phe508del mutation","volume":"20","author":"Dilokthornsakul","year":"2017","journal-title":"Value Health"},{"key":"key2025052621071600_ref180-bib180","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13023-018-0914-3","article-title":"Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States","volume":"13","author":"Sharma","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"key2025052621071600_ref181-bib181","doi-asserted-by":"crossref","first-page":"987","DOI":"10.18553\/jmcp.2018.24.10.987","article-title":"Cost-effectiveness and budget impact of lumacaftor\/ivacaftor in the treatment of cystic fibrosis","volume":"24","author":"Vadagam","year":"2018","journal-title":"J Managed Care Specialty Pharm"},{"key":"key2025052621071600_ref182-bib182","volume-title":"Pharmacoeconomic Review Report: Lumacaftor\/Ivacaftor (Orkambi): (Vertex Pharmaceuticals (Canada) Incorporated): Indication:\u00a0For the Treatment of Cystic Fibrosis in Patients Age 12 Years and Older Who Are Homozygous for the F508del Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene","author":"Canadian Agency for Drugs and Technologies in Health","year":"2016"},{"key":"key2025052621071600_ref183-bib183","volume-title":"Pharmacoeconomic Review Report: Lumacaftor\/Ivacaftor (Orkambi): (Vertex Pharmaceuticals (Canada) Incorporated): Indication: For the Treatment of Cystic Fibrosis in Patients 6 Years of Age and Older Who Are Homozygous for the F508del Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene","author":"Canadian Agency for Drugs and Technologies in Health","year":"2018"},{"key":"key2025052621071600_ref184-bib184","volume-title":"Lumacaftor and Ivacaftor Combination Therapy for Treating Cystic Fibrosis Homozygous for the F508del Mutation [TA786]","author":"National Institute for Health and Care Excellence (NICE)","year":"2016"},{"key":"key2025052621071600_ref185-bib185","volume-title":"Public Summary Document \u2013 July 2018 PBAC Meeting. Lumacaftor with Ivacaftor for Treatment of Patients with Cystic Fibrosis (CF) Aged \u2265 12 Years Who Are Homozygous for the F508del Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene","author":"Pharmaceutical Benefits Advisory Committee (PBAC)","year":"2018"},{"key":"key2025052621071600_ref186-bib186","volume-title":"Public Summary Document \u2013 July 2018 PBAC Meeting. (Lumacaftor\/Ivacaftor) for the Treatment of Patients with Cystic Fibrosis (CF) Aged 6\u201311 Years Who Are Homozygous for the F508del Mutation in the CF Transmembrane Conductance Regulator (CFTR) Gene","author":"Pharmaceutical Benefits Advisory Committee (PBAC)","year":"2018"},{"key":"key2025052621071600_ref187-bib187","volume-title":"Public Summary Document \u2013 July 2019 PBAC Meeting. Lumacaftor\/Ivacaftor Granules for Treatment of Cystic Fibrosis (CF) Patients Aged 2 Years and Older Who Are Homozygous for the F508del Mutation in the CF Transmembrane Conductance Regulator (CFTR) Gene","author":"Pharmaceutical Benefits Advisory Committee (PBAC)","year":"2019"},{"key":"key2025052621071600_ref188-bib188","volume-title":"Lumacaftor 200 mg, Ivacaftor 125 mg Film-Coated Tablet (Orkambi\u00ae)","author":"Scottish Medicines Consortium (SMC)","year":"2016"},{"key":"key2025052621071600_ref189-bib189","volume-title":"Lumacaftor and Ivacaftor 200 mg\/125 mg, 100 mg\/125 mg Film-Coated Tablets and 100 mg\/125 mg,150 mg\/188 mg Granules in Sachets (Orkambi\u00ae). [SMC2182]","author":"Scottish Medicines Consortium (SMC)","year":"2019"},{"key":"key2025052621071600_ref190-bib190","volume-title":"Public Summary Document \u2013 March 2019 PBAC Meeting. Tezacaftor\/Ivacaftor for Treatment of Cystic Fibrosis (CF) Patients Aged 12 Years and Older Who Have At least One Residual Function (RF) Mutation in the CFTR Gene","author":"Pharmaceutical Benefits Advisory Committee (PBAC)","year":"2019"},{"key":"key2025052621071600_ref191-bib191","volume-title":"Tezacaftor and Ivacaftor 100 mg\/150 mg Film-Coated Tablets (Symkevi\u00ae). [SMC2183]","author":"Scottish Medicines Consortium (SMC)","year":"2019"},{"key":"key2025052621071600_ref192-bib192","volume-title":"CADTH Reimbursement Review Elexacaftor\u2013Tezacaftor\u2013Ivacaftor and Ivacaftor (Trikafta). (Vertex Pharmaceuticals (Canada) Incorporated): Indication: Treatment of cystic fibrosis in patients aged \u2265 12 years who have at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.","author":"Canadian Agency for Drugs and Technologies in Health","year":"2021"},{"key":"key2025052621071600_ref193-bib193","volume-title":"Public Summary Document \u2013 December 2021 PBAC Meeting. Elexacaftor 100\u2009mg\/Tezacaftor 50\u2009mg\/Ivacaftor 75\u2009mg Film-Coated Tablets Co-Packaged with Ivacaftor 150\u2009mg Film-Coated Tablets","author":"Pharmaceutical Benefits Advisory Committee (PBAC)","year":"2021"},{"key":"key2025052621071600_ref196-bib196","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"key2025052621071600_ref197-bib197","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12955-015-0224-6","article-title":"Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches","volume":"13","author":"Acaster","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"key2025052621071600_ref198-bib198","first-page":"443","article-title":"Development of the Cystic Fibrosis Questionnaire-Revised preference based scoring algorithm","volume":"54","author":"Acaster","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"key2025052621071600_ref199-bib199","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jval.2022.12.002","article-title":"Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: estimating utilities from the Cystic Fibrosis Questionnaire-Revised","volume":"26","author":"Acaster","year":"2022","journal-title":"Value Health"},{"key":"key2025052621071600_ref200-bib200","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12890-019-0887-6","article-title":"Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study","volume":"19","author":"Bell","year":"2019","journal-title":"BMC Pulm Med"},{"key":"key2025052621071600_ref201-bib201","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1183\/09031936.00224911","article-title":"Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study","volume":"41","author":"Bradley","year":"2013","journal-title":"Eur Respir J"},{"key":"key2025052621071600_ref202-bib202","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/S1569-1993(21)01754-9","article-title":"Patient valuation of health-related quality of life associated with treatment burden and pulmonary exacerbation in cystic fibrosis","volume":"20","author":"Cameron","year":"2021","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref203-bib203","doi-asserted-by":"crossref","DOI":"10.3310\/hta17560","article-title":"Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model","volume":"17","author":"Tappenden","year":"2013","journal-title":"Health Technol Assess"},{"key":"key2025052621071600_ref204-bib204","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40273-013-0122-x","article-title":"The cost effectiveness of dry powder antibiotics for the treatment of pseudomonas aeruginosa in patients with cystic fibrosis","volume":"32","author":"Tappenden","year":"2014","journal-title":"PharmacoEconomics"},{"key":"key2025052621071600_ref205-bib205","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40273-017-0500-x","article-title":"An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis","volume":"35","author":"Tappenden","year":"2017","journal-title":"PharmacoEconomics"},{"key":"key2025052621071600_ref206-bib206","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1017\/S0266462322003373","article-title":"A model-based economic analysis of the CFHealthHub intervention to support adherence to inhaled medications for people with cystic fibrosis in the UK","volume":"39","author":"Tappenden","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"key2025052621071600_ref207-bib207","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3310\/pgfar09110","article-title":"An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT","volume":"9","author":"Wildman","year":"2021","journal-title":"Programme Grants Appl Res"},{"key":"key2025052621071600_ref208-bib208","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1592\/phco.20.15.1167.34583","article-title":"Health-related quality of life for adults with cystic fibrosis: a regression approach to assessing the impact of recombinant human DNase","volume":"20","author":"Johnson","year":"2000","journal-title":"Pharmacotherapy"},{"key":"key2025052621071600_ref209-bib209","volume-title":"Orkambi","author":"European Medicines Agency","year":"2015"},{"key":"key2025052621071600_ref210-bib210","volume-title":"Symkevi","author":"European Medicines Agency","year":"2018"},{"key":"key2025052621071600_ref211-bib211","volume-title":"Kaftrio","author":"European Medicines Agency","year":"2020"},{"key":"key2025052621071600_ref212-bib212","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jcf.2017.11.019","article-title":"Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: a longitudinal study using UK patient registry data","volume":"17","author":"Keogh","year":"2018","journal-title":"J Cyst Fibros"},{"key":"key2025052621071600_ref213-bib213","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jval.2012.04.013","article-title":"Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4","volume":"15","author":"Karnon","year":"2012","journal-title":"Value Health"},{"key":"key2025052621071600_ref214-bib214","volume-title":"NICE DSU Technical Support Document 15: Cost-Effectiveness Modelling Using Patient-Level Simulation","author":"Davis","year":"2012"},{"key":"key2025052621071600_ref215-bib215","volume-title":"National Cost Collection for the NHS 2021\/22","author":"NHS","year":"2023"},{"key":"key2025052621071600_ref217-bib217","volume-title":"Engauge Digitizer Software","author":"Mitchell","year":"2023"},{"key":"key2025052621071600_ref218-bib218","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"key":"key2025052621071600_ref219-bib219","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2337\/dc08-0466","article-title":"Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults","volume":"31","author":"Adler","year":"2008","journal-title":"Diabetes Care"},{"key":"key2025052621071600_ref220-bib220","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","article-title":"Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes","volume":"21","author":"Deeks","year":"2002","journal-title":"Stat Med"},{"key":"key2025052621071600_ref221-bib221","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/1097-0258(20000715)19:13<1707::AID-SIM491>3.0.CO;2-P","article-title":"Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses","volume":"19","author":"Engels","year":"2000","journal-title":"Stat Med"},{"key":"key2025052621071600_ref222-bib222","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLOS Med"},{"key":"key2025052621071600_ref223-bib223","unstructured":"NHS England. Annual Report on Cardiothoracic Organ Transplantation Report for 2021\/2022. London: NHS England; 2022."},{"key":"key2025052621071600_ref224-bib224","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/thorax.56.3.218","article-title":"Assessment of quality of life in lung transplantation using a simple generic tool","volume":"56","author":"Anyanwu","year":"2001","journal-title":"Thorax"},{"key":"key2025052621071600_ref225-bib225","doi-asserted-by":"crossref","first-page":"100182","DOI":"10.1016\/j.clinsp.2023.100182","article-title":"Health-related quality of life following lung transplantation for cystic fibrosis: a systematic review","volume":"78","author":"Raguragavan","year":"2023","journal-title":"Clinics"},{"key":"key2025052621071600_ref226-bib226","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2021"},{"key":"key2025052621071600_ref227-bib227","unstructured":"Cystic Fibrosis Trust. UK Cystic Fibrosis Registry: 2018 Annual Data Report. 2019."},{"key":"key2025052621071600_ref228-bib228","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1067\/mtc.2002.120342","article-title":"An economic evaluation of lung transplantation","volume":"123","author":"Anyanwu","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key2025052621071600_ref229-bib229","volume-title":"Unit Costs of Health and Social Care 2021","author":"Jones","year":"2021"},{"key":"key2025052621071600_ref230-bib230","volume-title":"NICE Health Technology Evaluations: The Manual. Process and Methods [PMG36]","author":"National Institute for Health and Care Excellence (NICE)","year":"2022"},{"key":"key2025052621071600_ref231-bib231","doi-asserted-by":"crossref","DOI":"10.1101\/2021.12.13.21267671","article-title":"Quality-adjusted life expectancy norms for the English population","author":"Schneider","year":"2021"},{"key":"key2025052621071600_ref232-bib232","volume-title":"Estimating EQ-5D by Age and Sex for the UK","author":"Hern\u00e1ndez Alava","year":"2022"},{"key":"key2025052621071600_ref233-bib233","volume-title":"Ivacaftor\u2013Tezacaftor\u2013Elexacaftor, Tezacaftor\u2013Ivacaftor and Lumacaftor\u2013Ivacaftor for Treating Cystic Fibrosis. TA988 Final Guidance","author":"National Institute for Health and Care Excellence","year":"2024"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047967","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/CPLD8546\/CPLD8546.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:51:12Z","timestamp":1748260272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/CPLD8546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":213,"alternative-id":["10.3310\/CPLD8546"],"URL":"https:\/\/doi.org\/10.3310\/cpld8546","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"02-2023","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"09-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"10-2024","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}